Integrated strategy for the production of therapeutic retroviral vectors

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 370-379

  Carrondo, Manuel ^a   Panet, Amos ^b   Wirth, Dagmar ^c   Coroadinha, Ana Sofia ^a   Cruz, Pedro ^a   Falk, Haya ^b   Schucht, Roland ^c   Dupont, Francis ^d   Geny Fiamma, Cécile ^e,f   Merten, Otto Wilhelm ^f   Hauser, Hansjörg ^c  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b HEBREW UNIVERSITY   (Israel)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d Henogen   (Belgium)

^e SANOFI PASTEUR   (France)

^f GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; DNA; RETROVIRUS VECTOR;

CELL LINE; CHROMOSOME; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; HELPER CELL; HUMAN; MICROCARRIER CULTURE; MOLECULAR CLONING; PROTEIN EXPRESSION; REVIEW; SKIN CULTURE; STORAGE; VIRUS PURIFICATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; COLLAGEN TYPE VII; DNA NUCLEOTIDYLTRANSFERASES; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; INDUSTRIAL MICROBIOLOGY; MICE; MICE, INBRED BALB C; RECOMBINATION, GENETIC; REPRODUCIBILITY OF RESULTS; RETROVIRIDAE;

EID: 79952650338     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.165     Document Type: Review

References (44)

1. Brill-Almon, E.B., Stern, D., Afik, J., et al. (2005). Ex vivo trans-duction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Mol. Ther. 12, 274-282.
2. Burns, J.C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.K. (1993). Vesicular stomatitis virus G glycoprotein pseudo-typed retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-8037. (Pubitemid 23260849)
3. Carrondo, M.J., Merten, O.W., Haury, M., Alves, P.M., and Coroadinha, A.S. (2008). Impact of retroviral vector components stoichiometry on packaging cell lines: effects on productivity and vector quality. Hum. Gene Ther. 19, 199-210. (Pubitemid 351271506)
4. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672. (Pubitemid 30241569)
5. Coroadinha, A.S., Schucht, R., Gama-Norton, L., et al. (2006). The use of Flp/FRT recombinase cassette in retroviral vector producer cell lines: flexibility and efficiency in transgene exchange. J. Biotechnol. 124, 457-468.
6. Cosset, F.L., Takeuchi, Y., Battini, J.L., et al. (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
7. Cruz, P.E., Silva, A.C., Roldao, A., et al. (2006). Screening of novel excipients for improving the stability of retroviral and adenoviral vectors. Biotechnol. Prog. 22, 568-576.
8. Cruz, P.E., Coroadinha, A.S., Rodriguez, T., et al. (2008). Production of retroviral vectors: From the producer cell to the final product. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Templeton, N.S., ed. (CRC Press, Boca Raton, FL) pp. 17-32.
9. Danos, O., and Mulligan, R.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and eco-tropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85, 6460-6464.
10. Davis, J.L., Witt, R.M., Gross, P.R., et al. (1997). Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum. Gene Ther. 8, 459-1467.
11. Edelstein, M.L., Abedi, M.R., and Wixon, J. (2007). Gene therapy clinical trials worldwide to 2007: An update. J. Gene Med. 9, 833-842. (Pubitemid 47543250)
12. Gama-Norton, L., Hermann, S., Schucht, R., et al. (2010). Retroviral vector performance upon integration in defined chromosomal loci of modular packaging cell lines. Hum. Gene Ther. 8, 979-991.
13. Green, H. (2008). The birth of therapy with cultured cells. Bioessays 30, 897-903.
14. Kunicher, N., Falk, H., Yaacov, B., et al. (2008). Tropism of lentiviral vectors in skin tissue. Hum. Gene Ther. 19, 255-266. (Pubitemid 351442729)
15. Lavillette, D., Ruggieri, A., Russell S.J., et al. (2000). Activation of a cell entry pathway common to type C mammalian ret-roviruses by soluble envelope fragments. J. Virol. 74, 295-304. (Pubitemid 30002909)
16. Lei, P., and Andreadis, S.T. (2005). Stoichiometric limitations in assembly of active recombinant retrovirus. Biotechnol. Bioeng. 90, 781-792. (Pubitemid 40756673)
17. Loew, R., Meyer, Y., Kuehlke, K., et al. (2010). A new PG13-based packaging cell line for stable production of clinical grade self inactivating g-retroviral vectors using targeted integration. Gene Ther. 17, 272-280.
18. Markowitz, D., Goff, S., and Bank, A. (1988). A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62, 1120-1124. (Pubitemid 18082924)
19. Merten, O.-W. (2004). State-of-the-art of the production of ret-roviral vectors. J. Gene Med. 6(Suppl. 1), S105-S124.
20. Merten, O.-W., Hannoun, C., Manuguerra, J.-C., et al. (1996). Development of a serum-free cell culture based human influenza virus vaccine production process. In Novel Strategies in the Design and Production of Vaccines. Cohen, S., and Shaffer-man, A., eds. (Plenum Press, New York) pp. 141-151. (Pubitemid 126441238)
21. Miller, A.D., and Buttimore, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell Biol. 6, 2895-2902.
22. Miller, A.D., and Chen, F. (1996). Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol. 70, 5564-5571. (Pubitemid 26240733)
23. Miller, A.D., Garcia, J.V., Von Suhr, N., et al. (1991). Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65, 2220-2224.
24. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cyto-toxicity assays. J. Immunol. Methods 65, 55-63. (Pubitemid 14203433)
25. Ory, D.S., Neugeboren, B.A., and Mulligan, R.C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 93, 11400-11406. (Pubitemid 26347133)
26. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
27. Pagès, J.C., and Bru, T. (2004). Toolbox for retrovectorologists. J. Gene Med. 6, S67-S82. (Pubitemid 40228018)
28. Pensiero, M.N., Wysocki, C.A., Knader, K., et al. (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7, 1095-1101. (Pubitemid 26202727)
29. Rigg, R.J., Chen, L., Dando, J.S., et al. (1996). A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety. Virology 218, 290-295. (Pubitemid 26133112)
30. Rodrigues, A.F., Carmo, M., Alves, P.M., et al. (2009). Retroviral vector production under serum deprivation: The role of lipids. Biotechnol. Bioeng. 104, 1171-1181.
31. Rodrigues, T., Carrondo, M.J.T., Alves, P.M., et al. (2007a). Purification of retroviral vectors for clinical application: Biological implications and technological challenges. J. Biotechnol. 127, 520-541. (Pubitemid 44827399)
32. Rodrigues, T., Carvalho, A., Carmo, M., et al. (2007b). Scaleable purification process for gene therapy retroviral vectors. J. Gene Med. 9, 233-243. (Pubitemid 46746314)
33. Schucht, R., Coroadinha, A.S., Zanta-Boussif, M.A., et al. (2006). A new generation of retroviral producer cells: Predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol. Ther. 14, 285-292. (Pubitemid 43964494)
34. Sinn, P.L., Sauter, S.L., and McCray, P.B., Jr. (2005). Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 12, 1089-1098. (Pubitemid 41030614)
35. Spitzer, D., Hauser, H., and Wirth, D. (1999). Complement resistant amphotropic retroviruses from murine packaging cells. Hum. Gene Ther. 10, 1893-1902. (Pubitemid 29357695)
36. Spitzer, D., Dittmar K.E., Rohde, M., Hauser, H., and Wirth, D. (2003). Green fluorescent protein-tagged retroviral envelope protein for analysis of virus-cell interactions. J. Virol. 77, 6070-6075. (Pubitemid 36538998)
37. Tamai, K., Kaneda, Y., and Uitto, J. (2009). Molecular therapies for heritable blistering diseases. Trends Mol. Med. 15, 285-292.
38. Verhoeyen, E., Hauser, H. and Wirth, D. (2001). Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. Hum. Gene Ther. 12, 933-944. (Pubitemid 32681857)
39. Ward, M., Sattler, R., Grossman, I.R., et al. (2003). A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. Mol. Ther. 8, 804-812. (Pubitemid 37527456)
40. Warnock, J.N., Merten, O.-W., and Al-Rubeai, M. (2006). Cell culture processes for the production of viral vectors for gene therapy purposes. Cytotechnology 50, 141-162.
41. Wirth, D., Gama-Norton, L., Riemer, P., et al. (2007). Road to precision: Recombinase-based targeting technologies for genome engineering. Curr. Opin. Biotechnol. 18, 411-419. (Pubitemid 350116585)
42. Yaacov, B., Elohaoo, E., Lazar, I., et al. (2008). Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 15, 795-807.
43. Yap, M.W., Kingsman, S.M., and Kingsman, A.J. (2000). Effects of stoichiometry of retroviral components on virus production. J. Gen. Virol. 81, 2195-2202.
44. 0 readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J. Virol. 76, 7209-7219.